QualityDipStocks / Health Care · Biotech
Revolution Medicines RVMD
Outside our quality screen, so we don’t track its dips. It’s 13% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $195.91price −2%
- Off 52-wk high
- −13%
- Risk vs market
- Above marketbeta 1.12
0 bullish · 5 bearish See why
Key levels
Every level vs today’s $191.31
- 52-wk lowlowest close, 1 year$58.57−69.4%
- PriceFri Oct 30 close$191.31you are here
- Market Valueavg paid since Sep 1$195.91+2.4%
- 52-wk highhighest close, 1 year$221.15+15.6%
Fair value estimate
No estimate for RVMD: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much RVMD moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 5.2× the S&P 500’s.
- Beta vs S&P 500
- 1.12
- Volatility
- 67% vs 13% SPY
- Correlation SPY
- 0.22
- Correlation QQQ
- 0.21
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 0 of 5
Nothing in our data makes a clear bull case right now.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$1.2B over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -48.8× over the last 12 months.
ProfitabilityLost $1.1B over the last 12 months (net income, SEC filings).
ProfitabilityReturn on equity fell 45 points in two fiscal years, to -69% in FY2025.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; no sales-growth data.
Who’s talking about it
Notable investors, executives, analysts and public figures on Revolution Medicines in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Biotech
All fundamentals
FCF yield -2.2% · ROE -58%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −2.2%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- n/anot reported in its SEC filings
- Price / book
- 25.01×
- Market cap
- $40.8Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $0
- Sales growth, 12 months
- n/ano year-ago 12-month revenue
- Sales growth, 3 yrs
- n/anot reported in its SEC filings
- Diluted EPS, 12 months
- −$5.95
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$1.1B
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- n/anot reported in its SEC filings
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- −58%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $2.0B
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -48.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$914M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +11.8%diluted shares vs a year ago
- Stock-based comp
- $118M
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Revolution Medicines’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
MV $195.91
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 49 · 5 days +2.3%
The business
FCF $-1.6B
- Free cash flow, 12 months−$1.6B
- Free-cash-flow yield−3.9%
- Return on invested capital−42%
- Return on equity−96%
Next report
Nov 4
- DateWed Nov 4, after the close
- Consensus EPS($2.34)
- Year-ago EPS($1.61)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
RVMD is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.